Metastatic Renal Cell Carcinoma Presenting as Foot Metastasis

2011 ◽  
Vol 101 (3) ◽  
pp. 265-268 ◽  
Author(s):  
Elie Choufani ◽  
Jerome Diligent ◽  
Laurent Galois ◽  
Didier Mainard

Malignant tumors frequently metastasize to bone centrally in the skeleton. Metastatic disease distal to the knee is unusual. Metastasis to the foot (acrometastasis) is rare (0.01%) and is usually a late manifestation of disseminated disease. The purpose of this article is to present a rare case of metastatic renal cell carcinoma with foot metastasis as the primary manifestation along with another rare localization of metastatic disease distal to the knee, in the contralateral tibial diaphysis. To highlight the delay in diagnosis of such a rare condition to consider it in the diagnosis of a painful foot, we also present a review of the literature. (J Am Podiatr Med Assoc 101(3): 265–268, 2011)

2011 ◽  
Vol 9 (9) ◽  
pp. 985-993 ◽  
Author(s):  
Robert Torrey ◽  
Philippe E. Spiess ◽  
Sumanta K. Pal ◽  
David Josephson

Both locally advanced and metastatic renal cell carcinoma (RCC) present a challenge in terms of their optimal management. This article reviews the literature and evaluates the role of surgery in the treatment of advanced RCC. Surgery is the optimal treatment for locally advanced RCC and minimal, resectable, metastatic disease. Patients with metastatic disease, and some forms of locally advanced disease, may also benefit from multimodal management with local surgical therapy and systemic treatment using either immunotherapy or targeted therapy. Regardless of the disease stage, patients with locally advanced or metastatic RCC represent heterogenous patient populations with different disease characteristics and risk factors. Individualization of care in the setting of a sound oncologic framework may optimize the risk/benefit ratio within individual patient cohorts.


2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Davi dos Santos Romao ◽  
Natally Horvat ◽  
Marianne Castro Gonçalves ◽  
Emerson Shigueaki Abe ◽  
Rodrigo Blanco Dumarco ◽  
...  

Splenic metastases are rare and usually occur in cases of disseminated disease. We report a case of a patient who had isolated splenic metastases with a previous history of left nephrectomy due to a renal cell carcinoma 11 years before. The aim of this report is to describe the case and review the literature of isolated splenic metastases due to renal carcinoma. This case emphasizes the importance of considering splenic metastatic disease even after many years of diagnosis of renal cell carcinoma.


Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 506
Author(s):  
Yoshihiro Morita ◽  
Kana Kashima ◽  
Mao Suzuki ◽  
Hiroko Kinosada ◽  
Akari Teramoto ◽  
...  

Renal cell carcinoma, which has clear cells in 70% of cases, has a high frequency of hematogenous distant metastases to lung, bone, liver, and other areas. Metastatic cancer accounts for 1 to 3% of malignant tumors in the stomatognathic region, and the metastasis of renal cell carcinoma to the oral mucosal tissue, though extremely rare, does occur. In addition, clear cells have been observed in some salivary gland cancers in the oral cavity. Therefore, the differential diagnosis of metastatic renal cell carcinoma and salivary gland cancer is important. This review discusses the differential diagnosis between metastatic renal cell carcinoma and malignant tumors of the salivary gland.


2019 ◽  
Vol 105 (6) ◽  
pp. NP72-NP74
Author(s):  
Emre Akar ◽  
Mehmet Haluk Yücel ◽  
Tunahan Şahin ◽  
Deniz Tural

Background: Cytotoxic and immunosuppressive therapies for cancer treatment may allow hepatitis reactivation. Hepatitis due to viral hepatitis reactivation is detected in 14%–25% of hepatitis B surface antigen (HBsAg)–positive cancer patients undergoing anticancer treatments. Drug toxicity may be confused with hepatitis reactivation, which may cause a delay in diagnosis. Case report: A 60-year-old man with metastatic renal cell carcinoma was treated with sunitinib. Sixteen months after sunitinib inception, liver enzymes were elevated and viral hepatitis reactivation was detected as hepatitis delta virus infection in the HBsAg-positive patient. Conclusion: Cancer patients should be screened for viral hepatitis prior to immunosuppressive therapy or chemotherapy.


2007 ◽  
Vol 177 (4S) ◽  
pp. 364-364 ◽  
Author(s):  
Surena F. Matin ◽  
Christopher G. Wood ◽  
Shi-Ming Tu ◽  
Nizar M. Tannir ◽  
Eric Jonasch

2005 ◽  
Vol 173 (4S) ◽  
pp. 173-174
Author(s):  
Quinton V. Cancel ◽  
Benjamin K. Yang ◽  
Zhen Su ◽  
Jens Dannull ◽  
Philipp Dahm ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 551-552
Author(s):  
Erich K. Lang ◽  
Richard J. Macchia ◽  
Raju Thomas ◽  
Ronald Davis ◽  
Douglas Slakey ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document